Inogen's (INGN) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Key Points

• Inogen's stock retains a "sell (e+)" rating from Weiss Ratings, while B. Riley has initiated coverage with a "buy" rating and a price target of $14.00.
• For the most recent quarter, Inogen reported earnings of ($0.15) per share, exceeding analyst expectations, and generated revenue of $92.28 million compared to the forecast of $90.40 million.
• Approximately 89.94% of Inogen's stock is held by institutional investors, indicating strong institutional interest in the company.

Inogen (NASDAQ:INGN - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by research analysts at Weiss Ratings in a report issued on Tuesday,Weiss Ratings reports.

Separately, B. Riley assumed coverage on Inogen in a report on Monday, June 16th. They set a "buy" rating and a $14.00 price target on the stock. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Inogen currently has a consensus rating of "Hold" and a consensus price target of $11.00.

Inogen Stock Up 2.5%

NASDAQ INGN traded up $0.20 during trading hours on Tuesday, hitting $8.24. The company had a trading volume of 71,107 shares, compared to its average volume of 261,993. Inogen has a fifty-two week low of $5.70 and a fifty-two week high of $12.91. The business has a fifty day simple moving average of $7.99 and a 200-day simple moving average of $7.18. The firm has a market cap of $222.89 million, a P/E ratio of -7.78 and a beta of 1.80.

Inogen (NASDAQ:INGN - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%.The firm had revenue of $92.28 million for the quarter, compared to analyst estimates of $90.40 million. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts forecast that Inogen will post -1.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of INGN. Integrated Wealth Concepts LLC acquired a new position in Inogen during the first quarter worth about $85,000. Algert Global LLC acquired a new position in Inogen during the first quarter worth about $89,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Inogen in the 2nd quarter valued at $90,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inogen in the 1st quarter valued at $99,000. Finally, CWM LLC boosted its position in shares of Inogen by 71.7% in the 1st quarter. CWM LLC now owns 14,647 shares of the medical technology company's stock valued at $104,000 after purchasing an additional 6,118 shares during the period. 89.94% of the stock is owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.